Drug Development · global
Weight-loss drugs go under the skin: First human data released for semaglutide implant
Vivani’s four-week trial in 20 people provides preliminary insights into the tolerability and drug release of a long-acting weight-loss implant. But the goal of dosing just once or twice a year remains some way from validation in humans.
If weight-loss treatment could shift from weekly injections to a single implant that continuously releases medication, the day-to-day burden of treatment might change. On November 12, Vivani Medical announced the first human results for NPM-139, its subcutaneous semaglutide implant: over four weeks, weight loss was similar in the implant group and the low-dose Wegovy injection group, and no adverse events judged to be treatment-related were reported in the implant group. However, this small trial is not yet sufficient to demonstrate long-term efficacy or confirm that the implant can reduce side effects.
The Phase 1 trial, called SLIM-1, enrolled 20 otherwise healthy participants with overweight or obesity at a single center in Australia. Ten received low-dose NPM-139, while the other 10 received weekly injections of 0.25 milligrams of Wegovy. The study used an open-label design, meaning participants and the research team knew which treatment was being used. It primarily assessed safety, tolerability, and changes in drug concentrations in the body, while also recording body weight.
After four weeks, body weight had decreased by 0.79% in the NPM-139 group and 0.82% in the Wegovy group. The two figures are similar, but the control group received a starting dose, so these results cannot establish that the implant provides weight-loss effects comparable to a full course of Wegovy treatment. The summary released this time also did not provide sufficient statistical evidence to establish equivalent efficacy.
On safety, none of the 10 participants in the implant group reported treatment-related adverse events, while five participants in the injection group experienced such events, all gastrointestinal. Neither group had any serious adverse events, and there were no complications during the implantation or removal procedures. These results support further research, but with only 10 people per group and four weeks of follow-up, it is difficult to identify less common risks or those that emerge later. “None reported” also does not mean that no risk exists.
Changes in drug concentrations offer another lead for development. According to the company’s announcement and RTTNews reporting, NPM-139 reached its maximum concentration approximately 16 days after administration, compared with approximately 2.4 days for the Wegovy control group; no rapid increase in drug exposure was observed in the implant group. Whether slower release can improve tolerability is a question that can be tested in future studies, but the difference in adverse events between the groups cannot currently be attributed directly to this feature.
NPM-139 is designed for administration once or twice a year, allowing the same drug to support long-term weight management through a different delivery method. However, four weeks of observation cannot answer whether the implant can maintain sufficient and stable drug concentrations over several months, nor has it demonstrated that it can increase the proportion of people who continue treatment. At this stage, the central advance is the availability of preliminary human data on drug release and procedural feasibility.
Vivani expects to begin a Phase 2 dose-finding trial in 2027, focusing on weight maintenance, and will also explore development possibilities in people who have never used GLP-1 drugs. Currently available public information comes mainly from preliminary results released by the company; the BioSpace publication carries the same press release and is not independent verification. Whether efficacy and safety can be maintained over a longer period and in more people in the next stage will be key to whether this implant technology can advance toward clinical use.